
Cogent Biosciences, Inc. (COGT) Stock Ticker
COGT right now
Market factors today
Unlock the full COGT picture
About Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
COGT stock facts
| Ticker symbol | COGT |
| Exchange | NASDAQ Global Select |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $5.5B |
| CEO | Andrew R. Robbins |
| Employees | 258 |
| Headquarters | Waltham, MA, US |
| IPO date | 2018-03-29 |
| Website | www.cogentbio.com |
What you can see for COGT on Tickr
Live COGT price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the COGT report.
Rankings
FAQ
What is the ticker symbol for Cogent Biosciences, Inc.?
The ticker symbol for Cogent Biosciences, Inc. is COGT, listed on the NASDAQ Global Select.
What is COGT?
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from…